NCT03573791Recruiting
Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer
Identification of Tissue Biomarkers for Predicting Neoadjuvant Chemoradio-resistance in Patients With Middle-low Local Advanced Rectal Cancer.
Source: ClinicalTrials.gov · Last updated 18 Aug 2026
Brief summary (registry, in English)
Neoadjuvant therapy has been widely applied to locally advanced rectal cancer. However, about 50% of patients receiving this therapy do not respond well as evidenced by the fact that their T or N stages are not effectively decreased judged by postoperative pathological examination. The purpose of this trail is to identify the biomarkers (from within patients' tumor mass before neoadjuvant therapy) to predict resistance to neoadjuvant therapy. These biomarkers can help stratify neoadjuvant-resistant patients towards surgery while avoiding unnecessary chemoradio-based neoadjuvant therapy.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 152 (estimated)
- First submitted
- 20 Jun 2018
- Start date
- 21 May 2018
- Primary completion date
- 21 May 2027
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Diseases
- Colorectal cancer
- NCT number
- NCT03573791
What you commit to
- Study type: Observational
- Planned participants: 152
- From 21 May 2018 to the primary completion date, 21 May 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- With intestinal obstruction or impending obstruction, or perforation.
- With other malignancies occurred within 5 years.
Who the study is looking for
- Histopathology proved to be adenocarcinoma of the rectum.
- The edge of tumor is within 12cm of anus margin.
- According to the eighth edition of AJCC TNM staging standard ,that staging for Ⅱ-Ⅲ period, as T3-T4, N0 or any T, N1-2.
- There is no history of chemotherapy, radiotherapy or immunotherapy before neoadjuvant therapy.
- Understand and agree to sign the informed consent for the study.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wuhan Union Hospital Coordinator of this site? Confirm its status | Wuhan | China | Recruiting |
| Hubei Cancer Hospital Coordinator of this site? Confirm its status | Wuhan | China | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.